| Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient PW Sperduto, S Mesko, J Li, D Cagney, A Aizer, NU Lin, E Nesbit, ... Journal of Clinical Oncology 38 (32), 3773-3784, 2020 | 321 | 2020 |
| Beyond an updated graded prognostic assessment (breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today PW Sperduto, S Mesko, J Li, D Cagney, A Aizer, NU Lin, E Nesbit, ... International Journal of Radiation Oncology* Biology* Physics 107 (2), 334-343, 2020 | 106 | 2020 |
| Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial D Pasalic, DA Kuban, PK Allen, C Tang, SM Mesko, SR Grant, ... International Journal of Radiation Oncology* Biology* Physics 104 (4), 790-797, 2019 | 78 | 2019 |
| Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival PW Sperduto, S Mesko, J Li, D Cagney, A Aizer, NU Lin, E Nesbit, ... Neuro-oncology 22 (9), 1359-1367, 2020 | 63 | 2020 |
| Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies S Mesko, K Sandler, J Cohen, G Konecny, M Steinberg, M Kamrava International Journal of Gynecologic Cancer 27 (2), 2017 | 42 | 2017 |
| Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma LE Spitler, P Boasberg, S O’Day, O Hamid, S Cruickshank, S Mesko, ... American journal of clinical oncology 38 (1), 61-67, 2015 | 42 | 2015 |
| Quantifying the ki‐67 heterogeneity profile in prostate cancer S Mesko, P Kupelian, DJ Demanes, J Huang, PC Wang, M Kamrava Prostate cancer 2013 (1), 717080, 2013 | 33 | 2013 |
| Proton therapy in non-small cell lung cancer S Mesko, D Gomez Current treatment options in oncology 19 (12), 76, 2018 | 29 | 2018 |
| Targeted prostate biopsy Gleason score heterogeneity and implications for risk stratification S Mesko, L Marks, O Ragab, S Patel, DA Margolis, DJ Demanes, ... American journal of clinical oncology 41 (5), 497-501, 2018 | 28 | 2018 |
| Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure D Pasalic, YI Lu, SL Betancourt-Cuellar, N Taku, SM Mesko, AF Bagley, ... Radiotherapy and Oncology 145, 178-185, 2020 | 25 | 2020 |
| Correlation of quantitative diffusion‐weighted and dynamic contrast‐enhanced MRI parameters with prognostic factors in prostate cancer MP Chung, D Margolis, S Mesko, J Wang, P Kupelian, M Kamrava Journal of medical imaging and radiation oncology 58 (5), 588-594, 2014 | 23 | 2014 |
| Estimating PTV margins in head and neck stereotactic ablative radiation therapy (SABR) through target site analysis of positioning and intrafractional accuracy S Mesko, H Wang, S Tung, C Wang, D Pasalic, BV Chapman, AC Moreno, ... International Journal of Radiation Oncology* Biology* Physics 106 (1), 185-193, 2020 | 20 | 2020 |
| Early clinical outcomes of ultrasound-guided CT-planned high-dose-rate interstitial brachytherapy for primary locally advanced cervical cancer S Mesko, U Swamy, SJ Park, L Borja, J Wang, DJ Demanes, M Kamrava Brachytherapy 14 (5), 626-632, 2015 | 19 | 2015 |
| Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing MS Ning, AH Klopp, A Jhingran, LL Lin, PJ Eifel, S Vedam, AA Lawyer, ... Brachytherapy 18 (4), 445-452, 2019 | 18 | 2019 |
| Multiparametric MRI identifies and stratifies prostate cancer lesions: implications for targeting intraprostatic targets ES Anderson, DJA Margolis, S Mesko, R Banerjee, PC Wang, ... Brachytherapy 13 (3), 292-298, 2014 | 17 | 2014 |
| Investigation of autosegmentation techniques on T2‐weighted MRI for off‐line dose reconstruction in MR‐linac workflow for head and neck cancers BA McDonald, CE Cardenas, N O'Connell, S Ahmed, MA Naser, ... Medical physics 51 (1), 278-291, 2024 | 14 | 2024 |
| Time-driven, activity-based cost analysis of radiation treatment options for spinal metastases D Boyce-Fappiano, MS Ning, NG Thaker, TA Pezzi, O Gjyshi, S Mesko, ... JCO Oncology Practice 16 (3), e271-e279, 2020 | 14 | 2020 |
| Development, implementation, and outcomes of a simulation-based medical education (SBME) prostate brachytherapy workshop for radiation oncology residents S Mesko, BV Chapman, C Tang, RJ Kudchadker, TL Bruno, J Sanders, ... Brachytherapy 19 (6), 738-745, 2020 | 12 | 2020 |
| BRAF-targeted therapy to treat superior vena cava syndrome in a patient with metastatic cancer SM Mesko, KJ Rosenthal, PD Boasberg, O Hamid Journal of Clinical Oncology 33 (25), e101-e103, 2015 | 11 | 2015 |
| Commercial insurance coverage of advanced radiation therapy techniques compared with American Society for Radiation Oncology model policies V Verma, EB Ludmir, SM Mesko, ED Brooks, A Augustyn, MT Milano, ... Practical radiation oncology 10 (5), 324-329, 2020 | 10 | 2020 |
